HGCO19 is India’s indigenous mRNA vaccine developed by the Pune-based Gennova Biopharmaceuticals. HGCO19 recently received Drug Controller General of India (DCGI) approval for phase I and II of the clinical trials on humans. The vaccine uses the same platform technology as those used by COVID-19 vaccines developed by Pfizer-BioNTech and Moderna. It was developed in collaboration with HDT Biotech Corporation of the US. This vaccine has already demonstrated the safety, immunogenicity and neutralisation antibody activity in animals.